| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| RILPIVIRINE
| RILPIVIRINE |
ANTIINFECTIVES | ORAL INTRAMUSCULAR | Tmax 4.5 HOUR PPB 99.7 PERCENT HT 50 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER OVER A WIDE PH RANGE | HIV-1 REVERSE TRANSCRIPTASE (EC50(HIV-1IIIB) = 0.73 NM) PDB 2ZE2 (CRYSTAL STRUCTURE OF L100I/K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH TMC278 (RILPIVIRINE), A NON-NUCLEOSIDE RT INHIBITOR) LIGAND CODE = T27 (link to the list of PDB complexes) Download experimental 3D coordinates of T27 with added hydrogens | HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE INHIBITOR CHEMBL247 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE Q72547 REVERSE TRANSCRIPTASE/RNASEH HUMAN IMMUNODEFICIENCY VIRUS 1 ENZYME HYDROLASE | EMA | |||
